Published in J Pharmacol Exp Ther on May 01, 1992
Reward processing by the opioid system in the brain. Physiol Rev (2009) 2.46
Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain Behav Immun (2008) 1.58
Hyperpolarization by opioids acting on mu-receptors of a sub-population of rat periaqueductal gray neurones in vitro. Br J Pharmacol (1994) 1.41
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience (2013) 1.14
From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics. Pharmacogenet Genomics (2009) 1.11
Genetic dissociation of two behaviors associated with nicotine addiction: beta-2 containing nicotinic receptors are involved in nicotine reinforcement but not in withdrawal syndrome. Psychopharmacology (Berl) (2006) 1.11
How to design an opioid drug that causes reduced tolerance and dependence. Ann Neurol (2010) 1.09
Presynaptic inhibition of diverse afferents to the locus ceruleus by kappa-opiate receptors: a novel mechanism for regulating the central norepinephrine system. J Neurosci (2008) 1.08
Orexin mediates the expression of precipitated morphine withdrawal and concurrent activation of the nucleus accumbens shell. Biol Psychiatry (2008) 1.07
The locus coeruleus: A key nucleus where stress and opioids intersect to mediate vulnerability to opiate abuse. Brain Res (2009) 1.06
Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacologic modulation of heroin vs food choice in heroin-dependent rhesus monkeys. Neuropsychopharmacology (2008) 1.06
Involvement of noradrenergic system within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats. Psychopharmacology (Berl) (2003) 1.03
Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat Rev Drug Discov (2012) 0.99
Narp regulates long-term aversive effects of morphine withdrawal. Behav Neurosci (2008) 0.98
Conditional deletion of the NMDA-NR1 receptor subunit gene in the central nucleus of the amygdala inhibits naloxone-induced conditioned place aversion in morphine-dependent mice. Exp Neurol (2008) 0.98
Differential desensitization of mu- and delta- opioid receptors in selected neural pathways following chronic morphine treatment. Br J Pharmacol (1996) 0.96
Augmented responses to morphine and cocaine in mice with a 12-lipoxygenase gene disruption. Psychopharmacology (Berl) (2003) 0.93
Acute opioid dependence: characterizing the early adaptations underlying drug withdrawal. Psychopharmacology (Berl) (2005) 0.93
micro-Opioid receptor endocytosis prevents adaptations in ventral tegmental area GABA transmission induced during naloxone-precipitated morphine withdrawal. J Neurosci (2010) 0.92
Social stress engages opioid regulation of locus coeruleus norepinephrine neurons and induces a state of cellular and physical opiate dependence. Neuropsychopharmacology (2013) 0.92
Dopamine-dependent increases in phosphorylation of cAMP response element binding protein (CREB) during precipitated morphine withdrawal in primary cultures of rat striatum. J Neurochem (2003) 0.91
An anatomical basis for opponent process mechanisms of opiate withdrawal. J Neurosci (2011) 0.89
Attenuation of acute and chronic effects of morphine by the imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline in rat locus coeruleus neurons. Br J Pharmacol (2003) 0.88
The role of TNFα in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats. Neuropsychopharmacology (2010) 0.87
Involvement of cyclic AMP systems in morphine physical dependence in mice: prevention of development of morphine dependence by rolipram, a phosphodiesterase 4 inhibitor. Br J Pharmacol (2001) 0.87
The α3β4* nicotinic ACh receptor subtype mediates physical dependence to morphine: mouse and human studies. Br J Pharmacol (2014) 0.86
Role of different brain structures in the behavioural expression of WIN 55,212-2 withdrawal in mice. Br J Pharmacol (2004) 0.84
Rapid neuroadaptation in the nucleus accumbens and bed nucleus of the stria terminalis mediates suppression of operant responding during withdrawal from acute opioid dependence. Neuroscience (2006) 0.83
Descending facilitatory pathways from the rostroventromedial medulla mediate naloxone-precipitated withdrawal in morphine-dependent rats. J Pain (2011) 0.82
Neuropeptide trefoil factor 3 attenuates naloxone-precipitated withdrawal in morphine-dependent mice. Psychopharmacology (Berl) (2014) 0.82
Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308. Br J Pharmacol (1995) 0.82
The role of functional postsynaptic NMDA receptors in the central nucleus of the amygdala in opioid dependence. Vitam Horm (2010) 0.81
Extracellular signal-regulated kinase activation in the amygdala mediates elevated plus maze behavior during opioid withdrawal. Behav Pharmacol (2009) 0.81
Effects of U-50488H and U-50488H withdrawal on c-fos expression in the rat paraventricular nucleus. Correlation with c-fos in brainstem catecholaminergic neurons. Br J Pharmacol (2003) 0.80
Morphine-induced trafficking of a mu-opioid receptor interacting protein in rat locus coeruleus neurons. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.80
CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats. Psychopharmacology (Berl) (2014) 0.79
2-MPPA, a selective glutamate carboxypeptidase II inhibitor, attenuates morphine tolerance but not dependence in C57/Bl mice. Psychopharmacology (Berl) (2005) 0.79
Nalfurafine, the kappa opioid agonist, inhibits icilin-induced wet-dog shakes in rats and antagonizes glutamate release in the dorsal striatum. Neuropharmacology (2006) 0.78
Activation of serotonin 5-HT2C receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice. Neuropharmacology (2015) 0.77
Orphan anxiety. Proc Natl Acad Sci U S A (1997) 0.77
GHB ameliorates naloxone-induced conditioned place aversion and physical aspects of morphine withdrawal in mice. Psychopharmacology (Berl) (2004) 0.76
An emerging new paradigm in opioid withdrawal: a critical role for glia-neuron signaling in the periaqueductal gray. ScientificWorldJournal (2012) 0.76
Suppression of naloxone-precipitated withdrawal jumps in morphine-dependent mice by stimulation of prostaglandin EP3 receptor. Br J Pharmacol (1995) 0.75
Changes in [3H]-UK 14304 binding to alpha 2-adrenoceptors in morphine-dependent guinea-pigs. Br J Pharmacol (1995) 0.75
IL-4 mediated by HSV vector suppresses morphine withdrawal response and decreases TNFα, NR2B, and pC/EBPβ in the periaqueductal gray in rats. Gene Ther (2017) 0.75
MnSOD mediated by HSV vectors in the periaqueductal gray suppresses morphine withdrawal in rats. Gene Ther (2017) 0.75
Effect of Pharmacological Modulation of the Endocannabinoid System on Opiate Withdrawal: A Review of the Preclinical Animal Literature. Front Pharmacol (2016) 0.75
Effect of Nimodipine on Morphine-related Withdrawal Syndrome in Rat Model: An Observational Study. J Pediatr Neurosci (2017) 0.75
Transition from moderate to excessive drug intake: change in hedonic set point. Science (1998) 5.66
Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science (1993) 3.67
Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res (2000) 3.33
Dramatic decreases in brain reward function during nicotine withdrawal. Nature (1998) 3.21
Excessive ethanol drinking following a history of dependence: animal model of allostasis. Neuropsychopharmacology (2000) 3.15
Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron (1998) 3.08
Suppression of psychoactive effects of cocaine by active immunization. Nature (1995) 3.05
Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet (2000) 3.04
Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology (1998) 2.96
Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend (1998) 2.94
Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci U S A (1998) 2.88
Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J Pharmacol Exp Ther (1993) 2.79
Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci (1995) 2.70
Effects of moderate alcohol consumption on the central nervous system. Alcohol Clin Exp Res (1998) 2.60
Intra-amygdala muscimol decreases operant ethanol self-administration in dependent rats. Alcohol Clin Exp Res (1996) 2.51
Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science (1997) 2.50
Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology (1991) 2.41
Animal models of drug craving. Psychopharmacology (Berl) (1993) 2.32
Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res (1993) 2.27
Cocaine vaccines: antibody protection against relapse in a rat model. Proc Natl Acad Sci U S A (2000) 2.16
Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology (Berl) (1984) 2.13
Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell (1994) 2.05
Persistent increase in the motivation to take heroin in rats with a history of drug escalation. Neuropsychopharmacology (2000) 2.04
CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. Psychopharmacology (Berl) (1991) 2.04
Long-lasting increase in the set point for cocaine self-administration after escalation in rats. Psychopharmacology (Berl) (1999) 2.01
Decreased brain reward produced by ethanol withdrawal. Proc Natl Acad Sci U S A (1995) 2.00
Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav (1992) 1.96
Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. J Neurosci (1996) 1.95
GABAA receptor antagonism in the extended amygdala decreases ethanol self-administration in rats. Eur J Pharmacol (1995) 1.93
Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science (1996) 1.91
Corticotropin releasing factor produces behavioural activation in rats. Nature (1982) 1.82
A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci U S A (2001) 1.78
Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci (2001) 1.78
Heroin and cocaine intravenous self-administration in rats: mediation by separate neural systems. Psychopharmacology (Berl) (1982) 1.76
Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther (1992) 1.76
Dopaminergic terminals in the rat cortex. Science (1973) 1.73
mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther (2000) 1.67
Performance norms for a rhesus monkey neuropsychological testing battery: acquisition and long-term performance. Brain Res Cogn Brain Res (1999) 1.66
Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci (1994) 1.65
Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci (1994) 1.61
Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res (1992) 1.60
Effects of the dopamine D-1 antagonist SCH 23390 microinjected into the accumbens, amygdala or striatum on cocaine self-administration in the rat. Brain Res (1995) 1.59
Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav (1999) 1.58
Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci (1982) 1.57
Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J Pharmacol Exp Ther (2000) 1.56
Neural substrates of opiate withdrawal. Trends Neurosci (1992) 1.52
Vertebrobasilar injuries following cervical manipulation. JAMA (1980) 1.51
Cocaine- but not food-seeking behavior is reinstated by stress after extinction. Psychopharmacology (Berl) (1997) 1.50
Modulation of social memory in male rats by neurohypophyseal peptides. Psychopharmacology (Berl) (1987) 1.49
Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacol Biochem Behav (1980) 1.48
Effects of dopamine D-1 and D-2 antagonists on cocaine self-administration under different schedules of reinforcement in the rat. J Pharmacol Exp Ther (1994) 1.47
Corticotropin-releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology (Berl) (1999) 1.46
Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci U S A (1997) 1.46
Operant self-administration of sweetened versus unsweetened ethanol: effects on blood alcohol levels. Alcohol Clin Exp Res (1999) 1.45
Genetic differences in response to novelty and spatial memory using a two-trial recognition task in mice. Neurobiol Learn Mem (2000) 1.44
Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology (1993) 1.43
Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science (1993) 1.43
Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. Pharmacol Biochem Behav (1982) 1.41
Complications associated with thoracocentesis. Chest (1986) 1.40
Corticotropin-releasing factor potentiates acoustic startle in rats: blockade by chlordiazepoxide. Psychopharmacology (Berl) (1986) 1.38
Oral ethanol self-administration in rats is reduced by the administration of dopamine and glutamate receptor antagonists into the nucleus accumbens. Psychopharmacology (Berl) (1992) 1.38
Drugs of abuse and the brain. Proc Assoc Am Physicians (1999) 1.35
Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res (1992) 1.35
Time-dependent quantifiable withdrawal from ethanol in the rat: effect of method of dependence induction. Alcohol (1996) 1.35
Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose-response analysis. J Pharmacol Exp Ther (1994) 1.35
Opponent process theory of motivation: neurobiological evidence from studies of opiate dependence. Neurosci Biobehav Rev (1989) 1.33
Increased ethanol self-administration in delta-opioid receptor knockout mice. Alcohol Clin Exp Res (2001) 1.29
Metabotropic glutamate 5 receptor antagonist MPEP decreased nicotine and cocaine self-administration but not nicotine and cocaine-induced facilitation of brain reward function in rats. Ann N Y Acad Sci (2003) 1.28
Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience (1990) 1.28
Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Brain Res (1999) 1.28
Increased ethanol self-administration after a period of imposed ethanol deprivation in rats trained in a limited access paradigm. Alcohol Clin Exp Res (1997) 1.26
Some evidence for the existence of dopaminergic neurons in the rat cortex. Brain Res (1973) 1.26
Prolonged tolerance, dependence and abstinence following subcutaneous morphine pellet implantation in the rat. Eur J Pharmacol (1994) 1.26
Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics. Biol Psychiatry (1986) 1.17
Dependence-induced alcohol drinking by alcohol-preferring (P) rats and outbred Wistar rats. Alcohol Clin Exp Res (2008) 1.16
The role of corticotropin-releasing factor in the anxiogenic effects of ethanol withdrawal. Ann N Y Acad Sci (1994) 1.16
Role of the corticotropin-releasing factor receptor type 2 in the control of food intake in mice: a meal pattern analysis. Eur J Neurosci (2007) 1.15
Central administration of an opiate antagonist decreases oral ethanol self-administration in rats. Alcohol Clin Exp Res (1999) 1.15
Corticotropin-releasing factor and behavior. Fed Proc (1985) 1.15
The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat. Behav Brain Res (1999) 1.14
CRF and urocortin decreased brain stimulation reward in the rat: reversal by a CRF receptor antagonist. Brain Res (2000) 1.14
The effects of 6-hydroxydopamine lesions of the nucleus accumbens and the mesolimbic dopamine system on oral self-administration of ethanol in the rat. Brain Res (1993) 1.14
Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by alpha-helical CRF (9-41). Neuropsychopharmacology (1989) 1.13
Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology (1998) 1.13
Relationship between the locomotor hyperactivity induced by A10 lesions and the destruction of the fronto-cortical dopaminergic innervation in the rat. Brain Res (1978) 1.13
Opiate withdrawal-induced fos immunoreactivity in the rat extended amygdala parallels the development of conditioned place aversion. Neuropsychopharmacology (2001) 1.13
Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. J Pharmacol Exp Ther (1988) 1.13